Bayern Munich executive Max Eberl revealed on Friday that the club has been aware of a neurological issue affecting star player Jamal Musiala for at least twelve months. The disclosure comes in response to inquiries regarding the player's recent health incidents, which included instances of collapses that sparked significant concern among the medical staff and fans.
Eberl clarified that the issue was identified through comprehensive medical screenings, and the club has been working with specialists to develop a management plan. The treatment, which was intended to stabilize Musiala's condition, had an unforeseen impact that led to the recent episodes. The board stressed that the player’s long-term health remains the absolute priority for the organization.
Medical experts have been tasked with re-evaluating the treatment protocol to prevent further occurrences. The club has maintained a high level of confidentiality throughout the process to protect Musiala’s privacy while ensuring he receives the best possible care. This development adds a layer of complexity to Bayern Munich's planning for the upcoming Bundesliga season, as they seek to ensure the player can perform without compromising his physical well-being.
Musiala has remained an integral part of the team, and his development continues to be closely monitored by both the coaching staff and the medical department. The news of the treatment-related collapses highlights the rigorous, and sometimes unpredictable, nature of managing high-performance athletes who undergo specialized medical care.
As the club navigates this challenge, they have reiterated their full support for Musiala. Further updates regarding his availability for upcoming matches will be provided based on the progress of the revised medical strategy. The focus now shifts toward ensuring a safe return to competitive play, with the medical staff working diligently to adjust his treatment plan for optimal safety and performance levels throughout the season.
